RLMD News and Press, Relmada Therapeutics Inc. From 10/13/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD ) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial . Unfortunately for RLMD stock, its RELIANCE III study did...

Relmada Therapeutics ( NASDAQ: RLMD ) said its drug REL-1017 did not meet the main goal of showing statistically significant improvement in depression symptoms compared to placebo in a phase 3 trial to treat patients with major depressive disorder. In the late stage stud...

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder PR Newswire RELIANCE I and II Adjunctive MDD Trials Continue to Advance CORAL GABLES, Fla. , ...

Summary 100% technical buy signals. 8 new highs and up 15.55% in the last month. Analyst's price targets between 42.00 to 90.00. The Chart of the Day belongs to the central nervous system treatment company Relmada Therapeutics ( RLMD ). I found the stock by sorti...

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder PR Newswire CORAL GABLES, Fla. , Sept. 20, 2022 /PRNewswire/ -- Relmada Therapeutic...

Summary We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid, effective, safe, and durable. Looking at the robust mechanism of acti...

Relmada Therapeutics, Inc. (RLMD) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer John Hixon - Head of Commercial Maged Shenouda - Chief Financial Off...

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results PR Newswire CORAL GABLES, Fla. , Aug. 11, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we," "us, "our"), a ...

Relmada Therapeutics ( NASDAQ: RLMD ) said on Tuesday the U.S. Food and Drug Administration had granted Fast Track designation to its drug, REL-1017, as a monotherapy to treat major depressive disorder. ( RLMD ) rose 3.3% premarket. For a fast tra...

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder PR Newswire CORAL GABLES, Fla. , Aug. 9, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stag...